Download Free Chronic Liver Disease New Targets And New Mechanisms Book in PDF and EPUB Free Download. You can read online Chronic Liver Disease New Targets And New Mechanisms and write the review.

Chronic liver failure is a frequent condition in clinical practice that encompasses all manifestations of patients with end-stage liver diseases. Chronic liver failure is a multiorgan syndrome that affects the liver, kidneys, brain, heart, lungs, adrenal glands, and vascular, coagulation, and immune systems. Chronic Liver Failure: Mechanisms and Management covers for the first time all aspects of chronic liver failure in a single book, from pathogenesis to current management. Each chapter is written by a worldwide known expert in their area and all provide the latest state-of-the-art knowledge. This volume is specifically designed to provide answers to clinical questions to all doctors dealing with patients with liver diseases, not only clinical gastroenterologists and hepatologists, but also to internists, nephrologists, intensive care physicians, and transplant surgeons.
Hepatic Fibrosis: Mechanisms and Targets is a complete volume of liver extracellular matrix biology, including molecular signaling pathways, cells and factors that modulate fibrogenesis and fibrosis. The book uses an integrated approach toward the molecular and cellular mechanisms involved in the synthesis and degradation of hepatic fibrotic tissue, emphasizing the possible molecular targets to fight fibrosis. This important reference describes, in detail and didactically, the cellular and molecular events that are conducive to fibrosis that leads to cirrhosis, hepatocellular carcinoma and death. The provided information allows readers to understand the molecular mechanisms of hepatic fibrogenesis to accelerate the development of new therapies. - Presents progression from inflammation to fibrosis, with a special focus on the molecular mechanisms involved - Didactically explains the participation of cells, cytokines and factors in profibrogenic pathways - Illuminates the causative participation of free radicals in liver fibrogenesis - Explains the role of gut dysbiosis in chronic liver diseases leading to fibrosis - Provides experimental models to study liver fibrosis and describes available, noninvasive monitoring methods
Twenty-nine articles by a richly international group of specialists offer new insights into many areas of liver disease. The first volume contains articles on mediators and regulation of liver disease and the immunological basis of liver injury, with individual topics that include the role of chemokines in liver pathophysiology, the basis for immune recognition of cellular targets in primary biliary cirrhosis, and the role of nitric oxide in liver disorders. Volume Two contains articles on pathophysiology, therapy, and diagnosis and includes chapters on molecular virology and therapeutic targets for the Hepatitis C virus, and new therapeutic approaches for hepatic fibrosis. The three editors are Ali (biochemistry, Deemed U., New Delhi, India), Scott L. Friedman (division of liver diseases, Mount Sinai School of Medicine, New York), and Derek A. Mann (molecular biology, Southampton U. Hospital, UK). Distributed in the US by Enfield. Annotation :2006 Book News, Inc., Portland, OR (booknews.com).
Since the publication of the first edition, there have been advances in both the diagnosis and the management of many of the cholestatic liver diseases. Cholestatic Liver Disease, Second Edition thoroughly updates the topics previously addressed, such as primary biliary cirrhosis, primary sclerosing cholangitis and cholestatic variants of drug hepatotoxicity and viral disease. New treatments, such as the development of the farnesoid X receptor agonists for the treatment of PBC, are highlighted. Current guidelines and areas of uncertainty are also covered. Additionally, new chapters have been added to reflect the changing landscape of cholestatic liver disease. Cholestatic Liver Disease, Second Edition is a concise yet comprehensive summary of the current status of the field and is of value to clinicians and researchers interested in patients with cholestatic liver disease provide that will help to guide patient management and stimulate investigative efforts.
Chronic liver disease is one of the most prevalent diseases in the developed world. The large amount of new knowledge has resulted in subspecialities, even in issues such as hepatology. Thus every day, it is more difficult to access all relevant information that is being published. Additionally, biomolecular techniques lead to a level of complexity that is only beneficial when dealt with by professionals. This book attempts to give a broad overview of the molecular biology of the liver, emphasizing how this knowledge is the basis of further treatment. Thus, pathophysiology and therapies are updated in viral hepatitis, hepatic encephalopathy and portal hypertension, among others. However, appended issues that apparently are less relevant such as the stem cell and endocannabinoids are included. These two issues will soon be of importance due to their close relationship with the liver tissue and especially with liver disease. There are also new paradigms such as cell death and the implication of the extracellular matrix, which are also addressed. In addition, important issues such as the stellate cells and their intimate relationship with fibrogenesis are treated in-depth. Also the fundamental role of endothelin in chronic liver disease is examined. Because of its prevalence, NASH was discussed with special interest, with a focus on the process from fatty liver to molecular biology of liver cells and metabolism in chronic liver disease. The authors believe that this is a broad vision that describes the basic pathophysiological mechanisms shared by many liver diseases, giving rational support for specific therapies.
Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series
From the contents: Mechanism of gastro-oesophageal reflux disease targets for anti-reflux therapy (J.-P. Galmiche and F. Zerbib). - Management of gastro-oesophageal reflux disease (J. Labenz). - Molecular mechanism in gastric carcinogenesis (P. Sipponen). - Gastric cancer management 1999 (G.N.J. Tytgat). - Mechanisms underlying non-ulcer dyspepsia (A.J.P.M. Smout). - Update on the management of non-ulcer dyspepsia (K.E.L. McColl). - Pathogenetic mechanisms in coeliac disease (S. Auricchio). - Management of coeliac disease (P.J. Kumar). - Immunoregulatory mechanisms in inflammatory bowel disease (S. Schreiber).